Deborah S. Yokoe*

, Steven W. Coon†, Rachel Dokholyan‡, Michael C. Iannuzzi†, Timothy F. Jones§, Sarah Meredith¶, Marisa Moore#, Lynelle Phillips**, Wayne Ray¶, Stephanie Schech††, Deborah Shatin††, and Richard Platt*†‡‡
Author affiliations: *Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; †Henry Ford Health System, Detroit, Michigan, USA; ‡Harvard Pilgrim Health Care, Boston, Massachusetts, USA; §Tennessee Department of Health, Nashville, Tennessee, USA; ¶Center for Education and Research in Therapeutics and Vanderbilt University, Nashville, Tennessee, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA; ††Center for Health Care Policy and Evaluation, Minneapolis, Minnesota, USA; and; ‡‡HMO Research Network Center for Education and Research on Therapeutics, Boston, Massachusetts, USA
Main Article
Table 1
Identification of tuberculosis (TB) cases by using pharmacy screening
| Cases |
Plan A (%) |
Plan B (%) |
Plan C (%) |
Total (%) |
| Total no. dispensed 2 or more anti-TB drugs |
73 |
28 |
143 |
244 |
| Matched to TB registry (previously reported TB cases) |
12 (17) |
6 (21) |
43 (30) |
61 (25) |
| Previously unreported TB cases (verified by record review) |
3 (4) |
1 (4) |
9 (6)a |
13 (5) |
| Not a TB case (verified by record review) |
55 (75) |
7 (25) |
91 (64) |
153 (63) |
| Case status not determined |
3 (4) |
14 (50) |
0 |
17 (7) |
Main Article
Top of Page